Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants

Overview

Journal Vaccines (Basel)

Date 2023 Mar 30

PMID 36992294

Authors

Mellissa C Alcantara

Yusuke Higuchi

Yuhei Kirita

Satoaki Matoba

Atsushi Hoshino

Affiliations

Soon will be listed here.

Abstract

The major concern with COVID-19 therapeutic monoclonal antibodies is the loss of efficacy against continuously emerging variants of SARS-CoV-2. To predict antibody efficacy against future Omicron subvariants, we conducted deep mutational scanning (DMS) encompassing all single mutations of the receptor-binding domain of the BA.2 strain utilizing an inverted infection assay with an ACE2-harboring virus and library spike-expressing cells. In the case of bebtelovimab, which preserves neutralization activity against BA.2 and BA.5, a broad range of amino acid substitutions at K444, V445, and G446, and some substitutions at P499 and T500, were indicated to achieve the antibody escape. Among subvariants with current rises in case numbers, BA2.75 with G446S partially evaded neutralization by bebtelovimab, while complete evasion was observed in XBB with V445P and BQ.1 with K444T. This is consistent with the DMS results against BA.2, highlighting the potential of DMS as a predictive tool for antibody escape.

Citing Articles

production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection.

Suzuki Y, Miyazaki T, Ida Y, Suzuki T, Itoh Y, Nakao S Mol Ther Nucleic Acids. 2025; 36(1):102467.

PMID: 40027884 PMC: 11869860. DOI: 10.1016/j.omtn.2025.102467.

Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity.

Roederer A, Cao Y, St Denis K, Sheehan M, Li C, Lam E Cell Rep Med. 2024; 5(12):101850.

PMID: 39657661 PMC: 11722104. DOI: 10.1016/j.xcrm.2024.101850.

Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development.

Huan X, Zhan J, Gao H Front Immunol. 2024; 15:1407149.

PMID: 39624100 PMC: 11609190. DOI: 10.3389/fimmu.2024.1407149.

Genomic surveillance and vaccine response to the dominant SARS-CoV-2 XBB lineage in Rio Grande do Sul.

Piccoli B, Y Castro T, Tessele L, Casarin B, Seerig A, Vieira A Sci Rep. 2024; 14(1):16831.

PMID: 39039137 PMC: 11263389. DOI: 10.1038/s41598-024-67828-7.

A universal recombinant adenovirus type 5 vector-based COVID-19 vaccine.

Li X, Peng Q, Liu X, Xu H, Liu J, Wu X Front Immunol. 2024; 15:1374486.

PMID: 38745651 PMC: 11091345. DOI: 10.3389/fimmu.2024.1374486.

References

Corti D, Purcell L, Snell G, Veesler D . Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021; 184(12):3086-3108. PMC: 8152891. DOI: 10.1016/j.cell.2021.05.005. View

Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M . LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022; 39(7):110812. PMC: 9035363. DOI: 10.1016/j.celrep.2022.110812. View

Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J . Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022; 602(7898):671-675. DOI: 10.1038/s41586-021-04389-z. View

Haddox H, Dingens A, Hilton S, Overbaugh J, Bloom J . Mapping mutational effects along the evolutionary landscape of HIV envelope. Elife. 2018; 7. PMC: 5910023. DOI: 10.7554/eLife.34420. View

Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci D . Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021; 385(21):1941-1950. DOI: 10.1056/NEJMoa2107934. View

Saito A, Tamura T, Zahradnik J, Deguchi S, Tabata K, Anraku Y . Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Cell Host Microbe. 2022; 30(11):1540-1555.e15. PMC: 9578327. DOI: 10.1016/j.chom.2022.10.003. View

VanBlargan L, Errico J, Halfmann P, Zost S, Crowe Jr J, Purcell L . An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022; 28(3):490-495. PMC: 8767531. DOI: 10.1038/s41591-021-01678-y. View

Chan K, Tan T, Narayanan K, Procko E . An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants. Sci Adv. 2021; 7(8). PMC: 7888922. DOI: 10.1126/sciadv.abf1738. View

Wong C . Subvariant 'soup' may drive wave. New Sci. 2022; 256(3411):11. PMC: 9635891. DOI: 10.1016/S0262-4079(22)01970-4. View

10.

Hoshino A, Wang W, Wada S, McDermott-Roe C, Evans C, Gosis B . The ADP/ATP translocase drives mitophagy independent of nucleotide exchange. Nature. 2019; 575(7782):375-379. PMC: 6858570. DOI: 10.1038/s41586-019-1667-4. View

11.

Starr T, Greaney A, Addetia A, Hannon W, Choudhary M, Dingens A . Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021; 371(6531):850-854. PMC: 7963219. DOI: 10.1126/science.abf9302. View

12.

Giroglou T, Cinatl Jr J, Rabenau H, Drosten C, Schwalbe H, Doerr H . Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol. 2004; 78(17):9007-15. PMC: 506966. DOI: 10.1128/JVI.78.17.9007-9015.2004. View

13.

Ikemura N, Taminishi S, Inaba T, Arimori T, Motooka D, Katoh K . An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo. Sci Transl Med. 2022; 14(650):eabn7737. PMC: 9097879. DOI: 10.1126/scitranslmed.abn7737. View

14.

Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J . Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022; 22(7):942-943. PMC: 9179126. DOI: 10.1016/S1473-3099(22)00365-6. View

15.

Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M . Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N Engl J Med. 2022; 386(15):1475-1477. PMC: 8929374. DOI: 10.1056/NEJMc2201933. View

16.

Chen P, Nirula A, Heller B, Gottlieb R, Boscia J, Morris J . SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2020; 384(3):229-237. PMC: 7646625. DOI: 10.1056/NEJMoa2029849. View

17.

Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L . BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022; 608(7923):593-602. PMC: 9385493. DOI: 10.1038/s41586-022-04980-y. View

18.

Starr T, Greaney A, Stewart C, Walls A, Hannon W, Veesler D . Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains. PLoS Pathog. 2022; 18(11):e1010951. PMC: 9674177. DOI: 10.1371/journal.ppat.1010951. View

19.

Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N . REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020; 370(6520):1110-1115. PMC: 7857396. DOI: 10.1126/science.abe2402. View

20.

Higuchi Y, Suzuki T, Arimori T, Ikemura N, Mihara E, Kirita Y . Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat Commun. 2021; 12(1):3802. PMC: 8217473. DOI: 10.1038/s41467-021-24013-y. View